newsfilter
← Latest News
GlobeNewswire·

Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights

Treated first FTD-GRN patient with Dose 2 PBFT02 and enrolled second patient; several additional patients being evaluated for trial eligibility Announced presentation of process development data of a high